2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Multiple Myeloma
5
Mucositis
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Febrile Neutropenia
2
Cytokine Release Syndrome
2
Burkitt Lymphoma
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Smoldering Multiple Myeloma
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Polycystic Ovary Syndrome
1
Pancreatic Neoplasms
1
Pancreatic Adenocarcinoma
1
Neurotoxicity Syndromes
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Inflammation
1
Hematologic Neoplasms
1
Early Stage Triple Negative ER Low Breast Cancer
1
Disease Progression
1
Cryopyrin-Associated Periodic Syndromes
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Arthritis, Rheumatoid
1
Interventions
Interleukin 1 Receptor Antagonist Protein
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Early Stage Triple Negative ER Low Breast Cancer
×
Interleukin 1 Receptor Antagonist Protein
×
Clear all
NCT06710197
2026-03-05
OZM-034
University Health Network, Toronto
Phase 2
Withdrawn